31 Million Americans Use GLP-1s - and There May be Hidden Dangers

About 12 percent of Americans—more than 31 million people—are currently using GLP-1 medications, according to estimates from the nonpartisan health policy group KFF. The drugs mimic a hormone that slows digestion, stimulates insulin production and helps people feel fuller longer. GLP-1s have helped drive the first sustained decline in U.S. obesity rates in more than a decade and have shown promise in treating conditions ranging from kidney disease to drug addiction.

But for thousands of patients, the side effects have been severe and, in some cases, life-altering.

More than 4,400 people have filed lawsuits over GLP-1 drugs, now consolidated into federal and state litigation, according to USA Today. Since the first cases were filed in August 2023, lawsuits have surged, primarily targeting Novo Nordisk, the Danish drugmaker behind Ozempic, Wegovy, Rybelsus, Victoza and Saxenda, as well as Indiana-based Eli Lilly, which produces Trulicity, Mounjaro and Zepbound. Plaintiffs broadly allege the companies failed to adequately warn patients and doctors about serious risks tied to the medications.

Please select this link to read the complete article from Inc.